Can a Two-Drug combo help young people with new type 1 diabetes keep making insulin?
NCT ID NCT06455319
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a low dose of anti-thymocyte globulin (ATG), followed by verapamil, can help preserve the body's ability to produce insulin in adolescents and young adults recently diagnosed with type 1 diabetes. The study will enroll 60 people aged 6 to 35 who have had diabetes for less than 100 days. Researchers will use a blood test to predict who will respond best to ATG, and then add verapamil to reduce stress on insulin-making cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-thymocyte globulin (ATG) and verapamil
What this could lead to
If successful, this could lead to a treatment that helps people with newly diagnosed type 1 diabetes keep making their own insulin longer, reducing the need for injected insulin.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The treatment may not work for all, and side effects from ATG or verapamil are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Davis Center for Diabetes
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Florida
RECRUITINGGainesville, Florida, 32610, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact